조기진통산모에 있어 Ritodrine Hydrochloride ( Yutopar ) 의 치료효과 = Effect of Ritodrine Hydrochloride ( Yutopar ) on Preterm Labor

다국어 초록 (Multilingual Abstract)

The perinatal mortality and morbidity associated with prematurity remains a major health problem. In recent years a group of betamimetic compounds has been used to stop premature labor. One of the most commonly used betamimetics is ritodrine hydrochloride (Yutopar). The purpose of this report is to present the result of retrospective study on the use of ritodrine hydrochloride in the management of preterm labor. The results of this study were as follows: 1. The mean gain time by ritodrine hydrochloride was 15.66 ± 21.19 days in patients with preterm labor. 2. According tot he increase of tocolysis score, the mean gain time was decreased. 3. Rupture of membrane was an important factor which affected the mean gain time by ritodrine hydrochloride. In patients with ruptured membrance, the mean gain time was 6.13 ± 12.33 days, which was significantly different from that in patients with intact membrane (20.11 ± 22.88 days)(P < 0.05). 4. During infusion of ritodrine hydrochloride, maternal pulse rate and fetal heart rate were increased, and maternal diastolic blood pressure was decreased. 5. The adverse side effects observed during ritodrine infusion were palpitation (68.3 %), nausea & vomiting (14.4 %), chest discomfort (14.4 %) in order of frequency. No severe side effects that stopped the ritodrine infusion were observed. 6. The Apgar scores of the newborn infants were 6.6 ± 2.1 at 1 minute and 7.7 ± 2.3 at 5 minutes, and birth weight was 2130 ± 769.3g and gestational age was 33.2 ± 3.9 weeks. 7. In infants with ritodrine treatment, the incidence of respiratory distress syndrome was 10.6 %, and it was high (13.3 %) in infants under 2,000 gm of birth weight compared with that (6.4 %) over 2,000 gm.